Education
About Us
Working with TipRanks
Follow Us
Immutep (IMMP)
NASDAQ:IMMP
IMMP Stock Chart & Stats
$2.04
-$0.05(-2.44%)
At close: 4:00 PM EST
$2.04
-$0.05(-2.44%)
Day’s Range― - ―
52-Week Range$1.32 - $3.53
Previous CloseN/A
Volume50.42K
Average Volume (3M)265.15K
Market Cap
$468.90M
Enterprise Value$611.30M
Total Cash (Recent Filing)$129.69M
Total Debt (Recent Filing)$1.63M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Feb 19, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding147,372,130
10 Day Avg. Volume167,940
30 Day Avg. Volume265,150
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)2.53
Price to Sales (P/S)71.92
P/FCF Ratio-5.84
Enterprise Value/Market Cap1.30
Enterprise Value/Revenue121.20
Enterprise Value/Gross Profit-10.85
Enterprise Value/Ebitda-9.72
Forecast
1Y Price Target
$12.00Price Target Upside488.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial Progress And De-riskingPivotal Phase 3 TACTI-004 trial has exceeded the enrollment threshold to trigger an independent futility analysis by the IDMC, creating an early de-risking event that could act as a catalyst for the stock.
Licensing And Commercial ExpansionExclusive licensing agreement with Dr. Reddy's for the lead asset opens major markets outside core territories, validates efti's global commercial potential and provides substantial non-dilutive capital to the company.
Manufacturing And Revenue ParticipationRetention of global manufacturing rights combined with a supply arrangement preserves long-term revenue participation from licensed regions while shifting commercialization responsibilities to the partner and reducing operational burden.
Bears Say
Immutep News
IMMP FAQ
What was Immutep’s price range in the past 12 months?
Immutep lowest stock price was $1.32 and its highest was $3.53 in the past 12 months.
What is Immutep’s market cap?
Immutep’s market cap is $468.90M.
When is Immutep’s upcoming earnings report date?
Immutep’s upcoming earnings report date is Feb 19, 2026 which is in 22 days.
How were Immutep’s earnings last quarter?
Immutep released its earnings results on Aug 29, 2025. The company reported -$0.197 earnings per share for the quarter, missing the consensus estimate of -$0.186 by -$0.011.
Is Immutep overvalued?
According to Wall Street analysts Immutep’s price is currently Undervalued.
Does Immutep pay dividends?
Immutep does not currently pay dividends.
What is Immutep’s EPS estimate?
Immutep’s EPS estimate is -0.18.
How many shares outstanding does Immutep have?
Immutep has 147,372,130 shares outstanding.
What happened to Immutep’s price movement after its last earnings report?
Immutep reported an EPS of -$0.197 in its last earnings report, missing expectations of -$0.186. Following the earnings report the stock price went down -3.012%.
Which hedge fund is a major shareholder of Immutep?
Currently, no hedge funds are holding shares in IMMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immutep Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$12.00 (488.24% Upside)
$12.00 (488.24% Upside)
Blogger Sentiment
Bullish
IMMP Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 564.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 3.3%
Last 30 Days ▲ 3.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
61.83%
12-Months-Change
Fundamentals
Return on Equity
-35.86%
Trailing 12-Months
Asset Growth
-23.58%
Trailing 12-Months
Company Description
Immutep
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
IMMP Stock 12 Month Forecast
Average Price Target
$12.00
▲(488.24% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
<0.01% Other Institutional Investors
99.41% Public Companies and
Individual Investors